Hangzhou Valgen Medtech Technology Co., Ltd. announced that it has received $200,000,000 in a round of funding co-led by DCP Investments and Sequoia China Investment Management LLP on May 6, 2021. The transaction included participation from new investors, Lake Bleu Capital (Hong Kong) Limited, Venus Medtech (Hangzhou) Inc. (SEHK:2500), China Life Health Equity Investment Fund, a fund managed by China Life Private Equity Investment Co., Ltd., Ascendum Capital Partners and returning investor, Qiming Weichuang Venture Capital Management (Shanghai) Company Limited.